The 36-month beta value for TVTX is also noteworthy at 0.89. There are mixed opinions on the stock, with 11 analysts rating it as a “buy,” 3 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for TVTX is 87.44M, and at present, short sellers hold a 12.63% of that float. The average trading volume of TVTX on May 01, 2025 was 1.81M shares.
TVTX) stock’s latest price update
Travere Therapeutics Inc (NASDAQ: TVTX)’s stock price has soared by 3.64 in relation to previous closing price of 20.08. Nevertheless, the company has seen a gain of 24.61% in its stock price over the last five trading days. businesswire.com reported 2025-04-29 that SAN DIEGO & ST. GALLEN, Switzerland–(BUSINESS WIRE)—- $TVTX–Travere Therapeutics, Inc., (NASDAQ: TVTX) and CSL Vifor are pleased to announce that the European Commission has approved the conversion of the conditional marketing approval (CMA) into a standard marketing authorization (MA) for FILSPARI for the treatment of adults with primary IgA nephropathy with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). Standard MA is granted for all member states of the Euro.
TVTX’s Market Performance
Travere Therapeutics Inc (TVTX) has seen a 24.61% rise in stock performance for the week, with a 16.13% gain in the past month and a 1.76% surge in the past quarter. The volatility ratio for the week is 6.19%, and the volatility levels for the past 30 days are at 7.99% for TVTX. The simple moving average for the last 20 days is 28.35% for TVTX’s stock, with a simple moving average of 26.94% for the last 200 days.
Analysts’ Opinion of TVTX
Wells Fargo, on the other hand, stated in their research note that they expect to see TVTX reach a price target of $27, previously predicting the price at $9. The rating they have provided for TVTX stocks is “Overweight” according to the report published on October 21st, 2024.
TVTX Trading at 11.95% from the 50-Day Moving Average
After a stumble in the market that brought TVTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -17.71% of loss for the given period.
Volatility was left at 7.99%, however, over the last 30 days, the volatility rate increased by 6.19%, as shares surge +19.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.16% lower at present.
During the last 5 trading sessions, TVTX rose by +24.61%, which changed the moving average for the period of 200-days by +112.35% in comparison to the 20-day moving average, which settled at $16.21. In addition, Travere Therapeutics Inc saw 19.46% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TVTX starting from Cline Christopher R., who sale 48 shares at the price of $13.14 back on Apr 11 ’25. After this action, Cline Christopher R. now owns 89,990 shares of Travere Therapeutics Inc, valued at $631 using the latest closing price.
Christopher Cline, the Officer of Travere Therapeutics Inc, proposed sale 48 shares at $13.14 during a trade that took place back on Apr 11 ’25, which means that Christopher Cline is holding shares at $631 based on the most recent closing price.
Stock Fundamentals for TVTX
Current profitability levels for the company are sitting at:
- -1.38 for the present operating margin
- 0.92 for the gross margin
The net margin for Travere Therapeutics Inc stands at -1.38. The total capital return value is set at -0.82. Equity return is now at value -246.75, with -46.37 for asset returns.
Based on Travere Therapeutics Inc (TVTX), the company’s capital structure generated 0.87 points at debt to capital in total, while cash flow to debt ratio is standing at -0.59. The debt to equity ratio resting at 6.8. The interest coverage ratio of the stock is -28.78.
Currently, EBITDA for the company is -265.77 million with net debt to EBITDA at -1.29. When we switch over and look at the enterprise to sales, we see a ratio of 9.39. The receivables turnover for the company is 8.6for trailing twelve months and the total asset turnover is 0.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.08.
Conclusion
In summary, Travere Therapeutics Inc (TVTX) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
